What Is Neratinib (Nerlynx)? FDA Approval, Licensing in Turkey, and Reimbursement Status

Extended Adjuvant Treatment for Breast Cancer: Nerlynx (Neratinib)

Developed to reduce recurrence risk in early HER2-positive breast cancer and control metastatic disease, Nerlynx (Neratinib)is an innovative targeted agent that irreversibly blocks intracellular signaling. Its clinical, pharmacological, and administration details follow.

Drug Profile

Approved Indications

Nerlynx is approved for two main breast cancer indications, as monotherapy or combination treatment:

• Extended Adjuvant Treatment: In adults with early hormone receptor-positive breast cancer and HER2 overexpression/amplification who completed trastuzumab-based adjuvant treatment less than 1 year earlier and are N2-positive (4 or more positive axillary lymph nodes), monotherapy is used for a maximum of 1 year to reduce the risk of recurrence.
• Advanced or Metastatic Disease: Used in advanced or metastatic HER2-positive breast cancer after at least two prior anti-HER2 regimens, combined with capecitabine (chemotherapy) as a treatment regimen.

FDA Approval History

Neratinib completed FDA approval processes based on survival results from international clinical trials:

• July 17, 2017: The FDA approved Nerlynx based on the Phase 3 ExteNET trial for extended adjuvant treatment of early HER2-positive breast cancer.
• February 26, 2020: Additional approval for metastatic HER2-positive disease with capecitabine followed the Phase 3 NALA trial.
• Clinical Study (ExteNET): In this double-blind trial of 2,840 women, Nerlynx reduced invasive disease recurrence or death in the intention-to-treat (ITT) population at the primary 2-year analysis by 33% (HR=0.67, p=0.011). The greatest benefit occurred in the hormone receptor-positive ER/PgR+ subgroup (HR=0.50).

What Is Nerlynx and How Does It Work?

Nerlynx is a small targeted molecule acting on the intracellular portions of cell-surface receptors. Unlike antibody treatments such as trastuzumab, it enters cells and inhibits key enzymes.

Administration and Dosage

The schedule and food requirements are crucial for effectiveness and side-effect management:

• Standard Dose: The recommended daily dose is 240 mg (6 film-coated 40 mg tablets), taken once daily at the same time.
• Metastatic Use: With capecitabine, take 240 mg PO continuously on days 1-21 of each 21-day cycle; capecitabine is given twice daily on days 1-14.
• Food Interaction (Critical): Tablets must be taken with food, not on an empty stomach . A high-fat meal increases systemic exposure (Cmax and AUC) by approximately 100% (2-fold).
• Administration Rules: Swallow tablets whole; do not chew, crush, or dissolve them. Grapefruit, pomegranate, and their juices may increase plasma concentrations and during treatment must not be consumed.
• Missed Doses: Do not double doses; resume the normal schedule the next day. In severe hepatic impairment (Child-Pugh C), the maintenance dose is reduced to 80 mg.

Pharmacokinetic Properties

Absorption, distribution, and elimination are as follows:

• Absorption and Distribution: Oral absorption is slow, reaching peak plasma concentration (Tmax) in about 7 hours. Binding to plasma proteins, mainly albumin and alpha-1 acid glycoprotein, exceeds 98%and is extensive.
• Metabolism (Biotransformation): Metabolism occurs mainly in the liver through CYP3A4 microsomal enzymes and, to a lesser extent, flavin-containing monooxygenase (FMO). There are 4 major circulating metabolites with similar potency: M3, M6, M7, and M11.
• Excretion: The main elimination route is fecal. Of a radiolabeled dose, 95.5% is excreted in feces, and only 0.96% through urine. No adjustment is therefore needed for mild or moderate renal impairment. Mean apparent plasma half-life is 17 hours.

Resistance Mechanisms

With prolonged treatment, tumor cells may develop defenses to evade the drug:

1. Target Receptor Mutations: Specific HER2/neu ATP-binding pocket mutations, such as the T798I gatekeeper mutation,may reduce covalent binding affinity and cause resistance.
2. Enzymatic Upregulation: Excess CYP3A4 activity in the liver or tumor microenvironment may accelerate metabolism and reduce therapeutic effectiveness.

Drug Interactions and Management

Side Effects and Toxicity Management

Gastrointestinal and dermatological reactions dominate the adverse-effect profile. Prophylaxis is crucial.

Special Populations and Precautions

• Older Patients (65 and Above): Discontinuation for adverse reactions is substantially higher than in younger patients (44.8% versus 25.2%). Monitor vomiting, dehydration, and acute kidney failure closely.
• Pregnancy and Contraception (Category D): Animal studies found embryo-fetal death and abnormalities. Women of childbearing potential must use highly effective contraception during treatment and for 1 month afterward . Because Nerlynx may reduce hormonal contraceptive effectiveness, add a barrier method (condom) . Men must use barrier contraception during treatment and for 3 months after the last dose.
• Lactation (Breastfeeding): Passage into human milk is unknown. Because risk to the infant cannot be excluded, breastfeeding during treatment is not recommended.
• Driving and Operating Machinery: Weakness, fatigue, dizziness, and dehydration-related syncope may mildly or moderately impair driving or machinery use.